DelveInsight’s “Opioid Use Disorder Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Opioid Use Disorder pipeline landscape. It covers the Opioid Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Opioid Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Opioid Use Disorder Pipeline? @ https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight

Key Takeaways from the Opioid Use Disorder Pipeline Report

• On May 22, 2026- Eli Lilly and Company conducted a phase 2 study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.
• On May 15, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
• In March 2026- Sonara Health initiated a Phase II of this SBIR aims to compare Sonara against usual take-homes to assess its impact on retention in care, opioid use, patient outcomes, and costs of care.
• In March 2026- Indivior Inc. announced a study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
• In March 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
• DelveInsight’s Opioid Use Disorder Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Opioid Use Disorder treatment.
• The leading Opioid Use Disorder Companies, such as GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
• Promising Opioid Use Disorder Therapies such as XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM203, and others.

Want to know which companies are leading innovation in Opioid Use Disorder? @ Opioid Use Disorder Clinical Trials Assessment

The Opioid Use Disorder Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Opioid Use Disorder Pipeline Report also highlights the unmet needs with respect to the Opioid Use Disorder.

Opioid Use Disorder Overview

Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Although opioids reduce the perception of pain but chronic use of opioids can cause distress and impairment. Opioid Related Disorder includes overpowering desire to use opioids, dependence, increased opioid tolerance, and addictions which represents the most severe form of the disorders. When discontinued, the individual suffers from withdrawal syndrome.

Opioid Use Disorder Emerging Drugs Profile

• ASP8062: Astellas Pharma

Astellas Pharma’s lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active γ-amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid Related Disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.

• OPNT-003 (Intranasal Nalmefene): Opiant Pharmaceuticals

Opiant Pharmaceuticals “breakthrough” drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.

If you’re tracking ongoing Opioid Use Disorder Clinical trials @ Opioid Use Disorder Treatment Drugs

The Opioid Use Disorder Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Opioid Use Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Use Disorder Treatment.
• Opioid Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Opioid Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Use Disorder market.

Opioid Use Disorder Companies

GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others

Opioid Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Opioid Use Disorder Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

From emerging drug candidates to competitive intelligence, the Opioid Use Disorder Pipeline Report @ Opioid Use Disorder Market Drivers and Barriers, and Future Perspectives

Scope of the Opioid Use Disorder Pipeline Report

• Coverage- Global
• Opioid Use Disorder Companies- GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
• Promising Opioid Use Disorder Therapies- XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM2038 and others.
• Opioid Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Opioid Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Opioid Use Disorder Treatment landscape in this detailed analysis @ Opioid Use Disorder Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Opioid Related Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Opioid Related Disorder – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Opioid Related Disorder Collaboration Deals
9. Mid Stage Products (Phase II)
10. ASP8062: Astellas Pharma
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. OPNT-003: Opiant Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Opioid Related Disorder Key Companies
19. Opioid Related Disorder Key Products
20. Opioid Related Disorder- Unmet Needs
21. Opioid Related Disorder- Market Drivers and Barriers
22. Opioid Related Disorder- Future Perspectives and Conclusion
23. Opioid Related Disorder Analyst Views
24. Opioid Related Disorder Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/opioid-related-disorder-pipeline-insight